| Document |
Document Title |
|
WO/2015/043473A1 |
Provided herein are glucopyranosyl derivatives used as sodium dependent glucose cotransporters (SGLTs) inhibitors and pharmaceutical uses thereof, particularly 6,8-dioxabicyclo [3.2.1] octane derivatives represented by Formula (I), or ph...
|
|
WO/2015/041235A1 |
[Problem] To provide a safe and efficient food material that is used for treating lifestyle-related diseases, is derived from a natural product, and can be expected to be effective by being taken in through daily life. [Solution] Provide...
|
|
WO/2015/036160A1 |
The present invention relates to a compound of formula (3Z,5S)-5-(hydroxymethyl)-1- [(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-meth19243yloxime, and/or an active metabolite thereof having antagonist action at the oxytocin...
|
|
WO/2015/037659A1 |
An aqueous solution formulation containing compound (I) can be manufactured by performing the following steps: a first step in which a solution is prepared by dissolving, in an organic solvent, a compound represented by formula (I) or a ...
|
|
WO/2015/031984A1 |
Compounds having a structure of Formula I: (Formula (I)) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R 3, R4, R5, X1, X2, X3 and X4 are as defined herein, and wherein the compound comprises at...
|
|
WO/2014/204281A9 |
The present invention relates to a hormone secretion regulator containing a telomerase-derived peptide, and specifically, a peptide comprising the amino acid sequence of SEQ ID NO: 1, the amino acid sequence having a homology of 80% or m...
|
|
WO/2015/034031A1 |
The present invention provides a novel crystal form of an arylalkylamine compound. Specifically, a novel crystal form of 4-(3S-(1R-(1-naphthyl)ethylamino)pyrrolidin-1- yl)phenylacetic acid has excellent stability, and is therefore useful...
|
|
WO/2015/033163A1 |
The invention provides a neurokinin 3 receptor (NKR3) antagonist for use in the treatment, prevention or amelioration of hot flushes in a human subject, for example a menopausal woman or a patient undergoing cancer therapy which affects ...
|
|
WO/2015/032272A1 |
The present invention relates to a C-aryl glucoside derivative, a preparation method for same, and medical applications thereof. Specifically, the present invention relates to compounds as represented by formula I, and, tautomers, enanti...
|
|
WO/2015/031284A1 |
This invention provides pharmaceutical formulations for the allosteric modulation of hemoglobin (S) and methods for their use in treating disorders mediated by hemoglobin (S) and disorders that would benefit from tissue and/or cellular o...
|
|
WO/2015/028938A1 |
The invention relates to naphthalene compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated wi...
|
|
WO/2015/031709A1 |
A rapid acting injectable formulation is provided comprising a therapeutic peptide and a vasodilatory agent. The therapeutic peptide has a molecular weight of greater than about 500 Daltons, and the vasodilatory agent is present in an am...
|
|
WO/2015/028409A1 |
The invention relates to selective estrogen receptor modulators (SERMs) and to methods for the preparation thereof, to the use thereof for the treatment and/or prophylaxis of disorders, and to the use thereof for producing medicaments fo...
|
|
WO/2015/027963A1 |
The present invention relates to an aromatic ring derivative, and pharmaceutical composition and use thereof, in particular to aromatic ring derivatives or hydrates as represented by general formula (II), solvates, stereoisomers thereof,...
|
|
WO/2015/027021A1 |
Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-KB activity, including metabolic and inflammatory and immune disease...
|
|
WO/2015/024450A1 |
The present invention provides a decapeptide derivative with LHRH receptor antagonist activity: R-D-Nal-D-Cpa-D-Pal-Ser-Aph(Hor)-D-Aph(Cbm)-Aaa7-Ilys-Pro-Aa
a10-NH2. The present invention further provides a preparation method of the deca...
|
|
WO/2015/024111A1 |
Provided are compounds of general formula A and A', wherein X1 and X2 are each C, CH or N; R3 and R4 are each H, optionally substituted C1-C30 saturated or unsaturated chemical group, or together form an optionally substituted C5-C8 cycl...
|
|
WO/2015/022831A1 |
[Problem] To provide: a composition for promoting estrogen secretion and that is able to promote estrogen secretion; an estrogen secretion aromatic composition; and an estrogen aromatic tool. [Solution] The composition that is for promot...
|
|
WO/2015/022830A1 |
[Problem] To provide: a composition that is for promoting estrogen secretion and that can promote the secretion of estrogen; an estrogen secretion aromatic composition; and an estrogen aroma tool. [Solution] By means of a method mediated...
|
|
WO/2015/021060A1 |
A palatable, single serving dietary supplement of amino acids that may be taken as a nutritional aid to improve health and well-being by promoting higher quality sleep, enhancing repair of muscular tissue after strenuous exercise in part...
|
|
WO/2015/017934A1 |
Described herein is the use of resistant potato starch as an effective dietary supplement offering protection against multiple metabolic risk factors that are associated with cardiovascular disease and diabetes, including High Density Li...
|
|
WO/2015/016494A1 |
The present invention relates to a pharmaceutical composition and to a health food composition for preventing and treating thyroid disease, the composition containing Maackia amurensis (Maackia amurensis Rupr.) extract and a fraction the...
|
|
WO/2015/000867A1 |
A compound of formula (I), or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, ...
|
|
WO/2014/207311A1 |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in trea...
|
|
WO/2014/207309A1 |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD and in treatment or preve...
|
|
WO/2014/207310A1 |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2to R7are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD and in treatment or prevent...
|
|
WO/2014/209978A1 |
The present invention relates to imidazole compounds, and pharmaceutically acceptable compositions thereof, useful as positive allosteric modulators of follicle stimulating hormone receptor (FSHR).
|
|
WO/2014/210489A1 |
A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.
|
|
WO/2014/203132A1 |
Benzopyran compounds with anti-estrogenic activity are provided as Formula I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII and XVIII. These compounds are useful for the treatment or prevention of a variety of c...
|
|
WO/2014/197979A1 |
The present disclosure provides agents capable of promoting endogenous steroid production (such as endogenous testosterone production) without altering the endogenous luteinizing hormone. The present disclosure also provides associated t...
|
|
WO/2014/197938A1 |
The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a Somatostatin analogs having agonistic activity i...
|
|
WO/2014/201450A1 |
Compositions and methods for testosterone booster injection solutions (TBIS) that includes testosterone cypionate in synergistic combination with anastrozole are disclosed. Disclosed TBIS may be administered for treating testosterone def...
|
|
WO/2014/197680A1 |
Provided herein are methods of treating and preventing pancreatitis, such as pancreatitis induced by glucagon- like peptide (GLP) agonists (such as GLP-1 agonists, for example Byetta®), by administration of a vitamin D receptor agonist ...
|
|
WO/2014/193587A1 |
Methods for treating androgen receptor related diseases and suppressing androgen receptor related function by administering an effective amount of minoxidil are provided. Methods for treating or prophylactically treating acne by administ...
|
|
WO/2014/190895A1 |
Provided are an imidazole diketone compound, and preparation method and use thereof. The compound has good pharmacokinetic and/or pharmacodynamic performance, thus may be used as an androgen receptor antagonist, and further is suitable t...
|
|
WO/2014/192294A1 |
The present invention relates to novel crystal forms of 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexa
hydro-pyrazolo[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-o
xo-ethyl]-isobutyramide L-tartrate. More particularly, the ...
|
|
WO/2014/190398A1 |
An inhibitor of amyloid fibril formation comprising: (a) a backbone that is hydrophobic or hydrophilic and comprises from 1 to about 1000 repeating units; (b) one or more hydrophobic or hydrophilic pendant chains linked to the backbone, ...
|
|
WO/2014/187343A1 |
Disclosed are a benzofuran derivative, a preparation method therefor, and a medical application thereof, specifically relating to a compound represented by general formula (I), a stereoisomer thereof, a hydrate thereof, a solvate thereof...
|
|
WO/2014/189836A1 |
The present invention is a compound comprising an NSAID portion and at least one of a progestin portion and a progesterone portion. The compound may take for instance the form of a pill or pellet (for oral internal use or for subdermal i...
|
|
WO/2014/183555A1 |
The present invention relates to a cycloalkyl acid derivative, a preparation method thereof, and a pharmaceutical application thereof, and in particular, the present invention relates to a cycloalkyl acid derivative represented by genera...
|
|
WO/2014/177623A1 |
The invention relates to a novel administration regime useful in the treatment of diseases or conditions where administration of insulin will be of benefit, as well as to kits for use in the same. In particular, the invention relates to ...
|
|
WO/2014/170898A1 |
Nucleic acid origami devices are provided that are non-immunogenic and/or resistant to nucleases, which may be activated by one or more external cues, such as ligands, glucose concentration or electromagnetic fields; or used for attenuat...
|
|
WO/2014/170362A1 |
The present invention relates to antibodies which bind human ghrelin and their use in methods of treating or preventing reduced appetite. The invention further relates to diagnostic tools for determining whether an individual is likely t...
|
|
WO/2014/170648A1 |
A method for treating polycystic ovarian syndrome and related conditions with a compound (I): or a pharmaceutically acceptable salt thereof.
|
|
WO/2014/169456A1 |
Provided in the present invention are the use of the following compound of formula A in the preparation of drugs for the treatment of tumor necrosis factor-related diseases and a method for treating tumor necrosis factor-related diseases...
|
|
WO/2014/170902A1 |
The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4'-O-methylhonokiol for t...
|
|
WO/2014/167230A1 |
The invention relates to a HIP/PAP protein or to one of the derivatives thereof for use thereof for treating or preventing insulin resistance in non-insulin dependent subjects.
|
|
WO/2014/166958A1 |
Spiroindoline derivatives, processes for their preparation and pharmaceutical compositions thereof, their use for the treatment of diseases, and their use for the manufacture of medicaments for the treatment of diseases, especially sex-h...
|
|
WO/2014/165956A1 |
The present invention relates to pharmaceutical compositions comprising a peptide that stimulates the release of gonadotropins and sexual steroids. More specifically, the present invention proposes pharmaceutical compositions comprising ...
|
|
WO/2014/165136A1 |
The present disclosure relates, in part, to a kit including at least one first prefilled syringe. The first prefilled syringe includes a dose of a hazardous agent in a first volume of a pharmaceutical composition comprising a pharmaceuti...
|
